Pharmaceutical Companies

Are PBMs Unjustly Profiting from 340B Drug Pricing Program?

June 2, 2022 - The Community Oncology Alliance (COA) has raised concerns that the high volume of contract pharmacies participating in the 340B drug pricing program allows pharmacy benefit managers (PBMs) to profit from the savings instead of directing savings toward underserved patients. In an amicus brief filed with the US Court of Appeals for the Seventh...

Read More


More Articles

Hospital Groups Urge Courts to Enforce 340B Drug Pricing Requirement

by Victoria Bailey

Five hospital organizations, including the American Hospital Association (AHA) and 340B Health, have urged two US Courts of Appeals to uphold the 340B drug pricing requirement for pharmaceutical...

Safety-Net Hospitals Lose $2.2M from 340B Drug Discount Limits

by Victoria Bailey

Safety-net hospitals have faced around $2.2 million in annualized losses due to pharmaceutical companies limiting 340B drug discounts at community and specialty pharmacies, a report from 340B Health...

Safety-Net Hospitals See Losses from 340B Drug Discount Limits

by Victoria Bailey

Safety-net hospitals have faced losses of up to $9 million due to a handful of drug companies limiting 340B discounts on prescription drugs dispensed through community pharmacies, according to a report...

Hospitals File Lawsuit to Settle 340B Issues with Pharma

by Jacqueline LaPointe

The American Hospital Association (AHA) and four other hospital organizations are suing HHS after the department failed to enforce 340B Drug Pricing Program requirements when major pharmaceutical...

AHA Slams Big Pharma Over Efforts to Limit 340B Drug Discounts

by Jacqueline LaPointe

The American Hospital Association (AHA) is demanding that five major pharmaceutical companies cease new efforts to curtail 340B drug discounts. In the past couple of weeks, Merck, Eli Lilly, Sanofi,...

Recent Articles